Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery (SWI Trial) (SWI)
Primary Purpose
INFECTION
Status
Terminated
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Vancomycin
No Vancomycin
Sponsored by
About this trial
This is an interventional prevention trial for INFECTION
Eligibility Criteria
Inclusion Criteria:
- Able to sign Informed Consent and Release of Medical Information Form
- Age ≥ 18 years
- Undergoing cardiac surgery with complete sternotomy (including re-operations)
Exclusion Criteria:
- Evidence of active infection (any culture positive or blood positive infection)
- Undergoing organ transplantation
- Patients with known hypersensitivity to vancomycin
- Pregnant or nursing women
- Mental impairment or other conditions that may not allow participant to understand the nature, significance, and scope of study
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Vancomycin
Control
Arm Description
During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in the following solution: 5 g vancomycin dissolved in 50 mL sterile water
During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in 50 mL sterile water. No Vancomycin
Outcomes
Primary Outcome Measures
Number of Sternal Wound Infections
The number of sternal wound infections at 3 months postoperative. This includes superficial incisional, deep incisional, and organ/space surgical site infections.
Secondary Outcome Measures
Number of Sternal Wound Infections
The number of sternal wound infections at 1 year postoperative. This includes superficial incisional, deep incisional, and organ/space surgical site infections.
Hospitalization
Duration of index hospitalization and subsequent re-admissions due to sternal wound infection.
Number of Participants With Use of Prophylactic Antibiotics
Number of participants with use of prophylactic antibiotics before surgery
Cost Analysis for Sternal Wound Infection Treatment
Cost analysis for sternal wound infection treatment post-operatively
Adverse Events
Adverse events during study participation
Full Information
NCT ID
NCT02374853
First Posted
February 23, 2015
Last Updated
November 1, 2022
Sponsor
University of Alberta
1. Study Identification
Unique Protocol Identification Number
NCT02374853
Brief Title
Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery (SWI Trial)
Acronym
SWI
Official Title
Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery (SWI Trial)
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Terminated
Why Stopped
the preliminary analysis of study result did not show significant benefit that was anticipate
Study Start Date
March 2015 (undefined)
Primary Completion Date
April 2019 (Actual)
Study Completion Date
April 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Alberta
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this research is to determine if using the antibiotic vancomycin as a preventative topical (on the surface of the skin) treatment during open-heart surgery will reduce the risk of developing a sternal wound infection.
Detailed Description
During open-heart surgery, an incision is made along the chest and the sternum (breastbone) is divided. The sternum is held open throughout the surgery so that the doctors can reach the heart. Sternal wound infection is an uncommon but serious complication of cardiac surgery that occurs when an infection develops at this site of entry. Sternal wound infections are associated with increased hospital stays, subsequent surgical procedures, and higher mortality rates.
The purpose of this research is to determine if using the antibiotic vancomycin as a preventative topical (on the surface of the skin) treatment during open-heart surgery will reduce the risk of developing a sternal wound infection. The results of this study could provide important information to guide new standards of practice in cardiac surgery. The ultimate goal of this research project is to improve patient care by reducing the number of sternal wound infections at our hospital.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
INFECTION
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
1037 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vancomycin
Arm Type
Experimental
Arm Description
During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in the following solution: 5 g vancomycin dissolved in 50 mL sterile water
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in 50 mL sterile water. No Vancomycin
Intervention Type
Drug
Intervention Name(s)
Vancomycin
Other Intervention Name(s)
Vancomycin Hydrochloride
Intervention Description
Topical prophylactic antibiotic
Intervention Type
Other
Intervention Name(s)
No Vancomycin
Other Intervention Name(s)
Sterile water
Intervention Description
Placebo: Sterile water. No Vancomycin.
Primary Outcome Measure Information:
Title
Number of Sternal Wound Infections
Description
The number of sternal wound infections at 3 months postoperative. This includes superficial incisional, deep incisional, and organ/space surgical site infections.
Time Frame
3 months postoperative
Secondary Outcome Measure Information:
Title
Number of Sternal Wound Infections
Description
The number of sternal wound infections at 1 year postoperative. This includes superficial incisional, deep incisional, and organ/space surgical site infections.
Time Frame
1 year postoperative
Title
Hospitalization
Description
Duration of index hospitalization and subsequent re-admissions due to sternal wound infection.
Time Frame
1 year postoperative
Title
Number of Participants With Use of Prophylactic Antibiotics
Description
Number of participants with use of prophylactic antibiotics before surgery
Time Frame
Assessed before surgery
Title
Cost Analysis for Sternal Wound Infection Treatment
Description
Cost analysis for sternal wound infection treatment post-operatively
Time Frame
1 year postoperative
Title
Adverse Events
Description
Adverse events during study participation
Time Frame
1 year postoperative
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Able to sign Informed Consent and Release of Medical Information Form
Age ≥ 18 years
Undergoing cardiac surgery with complete sternotomy (including re-operations)
Exclusion Criteria:
Evidence of active infection (any culture positive or blood positive infection)
Undergoing organ transplantation
Patients with known hypersensitivity to vancomycin
Pregnant or nursing women
Mental impairment or other conditions that may not allow participant to understand the nature, significance, and scope of study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Abbas Khani-Hanjani, MD
Organizational Affiliation
University of Alberta
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery (SWI Trial)
We'll reach out to this number within 24 hrs